(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number
WO 2005/044260 A1

(51) International Patent Classification[7]: A61K 31/404, 31/428, 31/426, 31/4709, 31/498, A61P 11/02, 11/06, 17/00, 19/02, 37/00, 43/00

(21) International Application Number: PCT/GB2004/004417

(22) International Filing Date: 19 October 2004 (19.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0324763.2 23 October 2003 (23.10.2003) GB

(71) Applicant *(for all designated States except US)*: **OXAGEN LIMITED** [GB/GB]; 91 Milton Park, Abingdon, Oxon OX14 4RY (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MIDDLEMISS, David** [GB/GB]; 62 Thorley Hill, Bishop's Stortford, Herts CM23 3NF (GB). **ASHTON, Mark, Richard** [GB/GB]; Evotec OAI Limited, 151 Milton Park, Abingdon, Oxon OX14 4RY (GB). **BOYD, Edward, Andrew** [GB/GB]; Evotec OAI Limited, 151 Milton Park, Abingdon, Oxon OX14 4RY (GB). **BROOKFIELD, Frederick, Arthur** [GB/GB]; Evotec OAI Limited, 151 Milton Park, Abingdon, Oxon OX14 4RY (GB).

(74) Agents: **ROBERTS, Alison, Christine** et al.; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPY



(I)

(57) Abstract: Compounds of general formula (I) wherein R^1, R^2, R^3 and R^4 are independently hydrogen, halo,C_1-C_6 alkyl, -O(C_1-C_6 alkyl), -CON(R^{11})$_2$, -SO^{11}, -SO_2R^{11}, -$SO_2N(R^{11})_2$, -N(R^{11})$_2$, -$NR^{11}COR^{11}$, -CO_2R^{11}, -COR^{11}, -SR^{11}, -OH, -NO_2 or -CN; each R^{11} is independently hydrogen or C_1 -C_6 alkyl; R^5 and R^6 are each independently hydrogen, or C_1-C_6 alkyl or together with the carbon atom to which they are attached forrn a C_3-C_7 cycloalkyl group; R^7 is hydrogen or C_1-C_6 alkyl; R^8 is an aromatic moiety optionally substituted with one or more substituents selected from halo, C_1-C_6 alkyl, -O(C_1-C_6)alkyl, -CON(R^{11})$_2$, -SOR^{11}, -SO_2R^{11}, -$SO_2N(R^{11})_2$, -N(R^{11})$_2$, -$NR^{11}COR^{11}$, -CO_2R^{11}, -COR^{11}, -SR^{11}, -OH, -NO_2 or -CN; wherein R^{11} is as defined above; R^9 is hydrogen, or C_1-C_6 alkyl; provided that: R^8 is not phenyl substituted with -COOH; when any two of R^1, R^2, R^3 and R^4 are hydrogen, neither of the other two of R^1, R^2, R^3 and R^4 is C_3-C_6 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in the preparation of pharmaceuticals for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

WO 2005/044260 A1